Olaparib maintenance therapy in patients (pts) with a BRCA1 and/or BRCA2 mutation (BRCAm) and newly diagnosed advanced ovarian cancer (OC): SOLO1 China cohort

被引：0
|
作者：
Wu, L. [1 ]
Zhu, J. [2 ]
Yin, R. [3 ,4 ]
Wu, X. [5 ]
Lou, G. [6 ]
Wang, J. [7 ]
Gao, Y. [8 ]
Kong, B. [9 ]
Lu, X. [10 ]
Zhou, Q. [11 ]
Wang, Y. [12 ]
Chen, Y. [13 ]
Lu, W. [14 ]
Li, W. [15 ]
Cheng, Y. [16 ]
Liu, J. [17 ,18 ]
Ma, X. [19 ]
Zhang, J. [19 ]
机构：
[1] Chinese Acad Med Sci, Canc Hosp, Gynecol Oncol, Beijing, Peoples R China
[2] Zhejiang Canc Hosp, Dept Gynecol Oncol, Hangzhou, Zhejiang, Peoples R China
[3] Sichuan Univ, Dept Gynecol & Obstet, Chengdu, Sichuan, Peoples R China
[4] Sichuan Univ, West China Univ Hosp 2, Minist Educ, Key Lab Obstet & Gynecol & Pediat Dis & Birth Def, Chengdu, Sichuan, Peoples R China
[5] Fudan Univ, Obstet & Gynecol Hosp, Dept Gynecol Oncol, Shanghai, Peoples R China
[6] Harbin Med Univ, Canc Hosp, Dept Gynecol & Oncol, Harbin, Heilongjiang, Peoples R China
[7] Hunan Canc Hosp, Dept Gynecol Oncol, Changsha, Hunan, Peoples R China
[8] Beijing Canc Hosp, Dept Gynecol Oncol, Beijing, Peoples R China
[9] Shandong Univ, Qilu Hosp, Dept Obstet & Gynecol, Jinan, Shandong, Peoples R China
[10] Fudan Univ, Dept Gynecol Oncol, Obstet & Gynecol Hosp, Shanghai, Peoples R China
[11] Chongqing Canc Hosp, Chongqing Off Canc Control & Res, Chongqing, Peoples R China
[12] Xian Jiatong Univ, Sch Med, Affiliated Hosp 1, Xian, Shaanxi, Peoples R China
[13] Soochow Univ, Affiliated Hosp 1, Dept Obstet & Gynecol, Suzhou, Peoples R China
[14] Zhejiang Univ, Womens Hosp, Sch Med, Hangzhou, Zhejiang, Peoples R China
[15] First Hosp Jilin Univ, Ctr Oncol, Changchun, Jilin, Peoples R China
[16] Jilin Canc Hosp, Div Thorac Oncol, Changchun, Jilin, Peoples R China
[17] Sun Yat Sen Univ, State Key Lab Oncol South China, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[18] Sun Yat Sen Univ, Dept Gynecol Oncol, Ctr Canc, Guangzhou, Guangdong, Peoples R China
[19] AstraZeneca, Clin Dev, Shanghai, Peoples R China
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
230P
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Overall Survival With Maintenance Olaparib at a 7-Year Follow-up in Patients With Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1/GOG 3004 Trial
    DiSilvestro, Paul
    Banerjee, Susana
    Colombo, Nicoletta
    Scambia, Giovanni
    Kim, Byoung-Gie
    Oaknin, Ana
    Friedlander, Michael
    Lisyanskaya, Alla
    Floquet, Anne
    Leary, Alexandra
    Sonke, Gabe S.
    Gourley, Charlie
    Oza, Amit
    Gonzalez-Martin, Antonio
    Aghajanian, Carol
    Bradley, William
    Mathews, Cara
    Liu, Joyce
    McNamara, John
    Lowe, Elizabeth S.
    Ah-See, Mei-Lin
    Moore, Kathleen N.
    OBSTETRICAL & GYNECOLOGICAL SURVEY, 2023, 78 (01) : 25 - 27
  • [22] Predictors of BRCA1/BRCA2 mutation testing in newly diagnosed breast cancer patients.
    Schwartz, M
    Lerman, C
    Brogan, B
    Peshkin, B
    Isaacs, C
    DeMarco, T
    Pennanen, M
    CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION, 2003, 12 (11) : 1328S - 1329S
  • [23] Efficacy of Maintenance Olaparib for Patients With Newly Diagnosed Advanced Ovarian Cancer With a BRCA Mutation: Subgroup Analysis Findings From the SOLO1 Trial (Aug, 10.1200/JCO.20.00799, 2020)
    DiSilvestro
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (12) : 1414 - 1414
  • [24] Implications of BRCA1 and BRCA2 mutations on taxane sensitivity in patients (pts) with advanced ovarian cancer.
    Tan, D. S. P.
    Yap, T. A.
    Hutka, M. M.
    Roxburgh, P.
    Grzybowska, E.
    Gourley, C.
    Gore, M. E.
    Kaye, S. B.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [25] Patient-centred outcomes with maintenance olaparib in newly diagnosed patients with advanced ovarian cancer (OC) and a BRCA mutation in the phase III SOLO1 trial to support the clinical benefit of prolongation of progression-free survival (PFS)
    Friedlander, M. L.
    Moore, K. N.
    Colombo, N.
    Scambia, G.
    Kim, B-G.
    Oaknin, A.
    Lisyanskaya, A.
    Floquet, A.
    Leary, A.
    Sonke, G. S.
    Gourley, C.
    Banerjee, S.
    Oza, A.
    Gonzalez-Martin, A.
    Aghajanian, C.
    Bradley, W.
    Lowe, E.
    Hettle, R.
    Flood, E.
    Disilvestro, P.
    ANNALS OF ONCOLOGY, 2019, 30
  • [26] Impact of BRCA1/BRCA2 counseling and testing on newly diagnosed breast cancer patients
    Schwartz, MD
    Lerman, C
    Brogan, B
    Peshkin, BN
    Halbert, CH
    DeMarco, T
    Lawrence, W
    Main, D
    Finch, C
    Magnant, C
    Pennanen, M
    Tsangaris, T
    Willey, S
    Isaacs, C
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (10) : 1823 - 1829
  • [27] Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers
    Kotsopoulos, J
    Lubinski, J
    Neuhausen, SL
    Lynch, HT
    Rosen, B
    Ainsworth, P
    Moller, P
    Ghadirian, P
    Isaacs, C
    Karlan, B
    Sun, P
    Narod, SA
    GYNECOLOGIC ONCOLOGY, 2006, 100 (01) : 83 - 88
  • [28] Inactivation of BRCA1 and BRCA2 in ovarian cancer
    Hilton, JL
    Geisler, JP
    Rathe, JA
    Hattermann-Zogg, MA
    DeYoung, B
    Buller, RE
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2002, 94 (18): : 1396 - 1406
  • [29] The Contribution of BRCA1 and BRCA2 to Ovarian Cancer
    Ramus, Susan J.
    Gayther, Simon A.
    MOLECULAR ONCOLOGY, 2009, 3 (02) : 138 - 150
  • [30] Cost-effectiveness analysis of olaparib as a maintenance monotherapy for patients with newly diagnosed advanced ovarian cancer and a BRCA1/2 mutation: A United States payer perspective
    Muston, D. R. G.
    Monberg, M. J.
    McLaurin, K.
    Sackeyfio, A.
    Hettle, R.
    Signorovitch, J.
    Swallow, E.
    Gao, W.
    Zhang, S.
    Kalemaj, I.
    Moore, K. N.
    GYNECOLOGIC ONCOLOGY, 2020, 159 : 140 - 141
12345